These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 11751017)
81. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704 [TBL] [Abstract][Full Text] [Related]
82. A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo. Tarasenko N; Cutts SM; Phillips DR; Berkovitch-Luria G; Bardugo-Nissim E; Weitman M; Nudelman A; Rephaeli A Biochem Pharmacol; 2014 Mar; 88(2):158-68. PubMed ID: 24463168 [TBL] [Abstract][Full Text] [Related]
83. Anti-proliferate and apoptosis triggering potential of methotrexate-transferrin conjugate encapsulated PLGA nanoparticles with enhanced cellular uptake by high-affinity folate receptors. Parmar A; Jain A; Uppal S; Mehta SK; Kaur K; Singh B; Sandhir R; Sharma S Artif Cells Nanomed Biotechnol; 2018; 46(sup2):704-719. PubMed ID: 29745729 [TBL] [Abstract][Full Text] [Related]
84. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. He M; Zhao Z; Yin L; Tang C; Yin C Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302 [TBL] [Abstract][Full Text] [Related]
85. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Harrington KJ; Rowlinson-Busza G; Uster PS; Stewart JS Cancer Chemother Pharmacol; 2000; 46(1):10-8. PubMed ID: 10912572 [TBL] [Abstract][Full Text] [Related]
86. Pharmacokinetics of doxorubicin in glioblastoma multiforme following ultrasound-Induced blood-brain barrier disruption as determined by microdialysis. Lin YL; Wu MT; Yang FY J Pharm Biomed Anal; 2018 Feb; 149():482-487. PubMed ID: 29175555 [TBL] [Abstract][Full Text] [Related]
87. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245 [TBL] [Abstract][Full Text] [Related]
88. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW; Henderson AJ; Klunk LJ; Knipe JO Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510 [TBL] [Abstract][Full Text] [Related]
89. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206 [TBL] [Abstract][Full Text] [Related]
90. cRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo. Zhong Y; Wang C; Cheng R; Cheng L; Meng F; Liu Z; Zhong Z J Control Release; 2014 Dec; 195():63-71. PubMed ID: 25108151 [TBL] [Abstract][Full Text] [Related]
91. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Chu AC; Tsang SY; Lo EH; Fung KP Life Sci; 2001 Dec; 70(5):591-601. PubMed ID: 11811903 [TBL] [Abstract][Full Text] [Related]
92. Toxicological evaluation of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine (VNP40101M), a novel alkylating agent with potential antitumor activity, with intravenous administration in rats and dogs. Lee KC; Almassian B; Noveroske J Int J Toxicol; 2002; 21(1):23-38. PubMed ID: 11936896 [TBL] [Abstract][Full Text] [Related]
93. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Remsen LG; Trail PA; Hellström I; Hellström KE; Neuwelt EA Neurosurgery; 2000 Mar; 46(3):704-9. PubMed ID: 10719867 [TBL] [Abstract][Full Text] [Related]
94. Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Bertazzoli C; Rovero C; Ballerini L; Lux B; Balconi F; Antongiovanni V; Magrini U Toxicol Appl Pharmacol; 1985 Jul; 79(3):412-22. PubMed ID: 3862266 [TBL] [Abstract][Full Text] [Related]
95. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Tian XH; Lin XN; Wei F; Feng W; Huang ZC; Wang P; Ren L; Diao Y Int J Nanomedicine; 2011; 6():445-52. PubMed ID: 21445277 [TBL] [Abstract][Full Text] [Related]
96. Targeted Propolis-Loaded Poly (Butyl) Cyanoacrylate Nanoparticles: An Alternative Drug Delivery Tool for the Treatment of Cryptococcal Meningitis. Thammasit P; Tharinjaroen CS; Tragoolpua Y; Rickerts V; Georgieva R; Bäumler H; Tragoolpua K Front Pharmacol; 2021; 12():723727. PubMed ID: 34489710 [TBL] [Abstract][Full Text] [Related]
97. [Nitric oxide donor nitrosorbide potentiates the antitumor effect of doxorubicin against experimental glioblastoma]. Alekseeva AI; Kudelkina VV; Kosyreva AM; Drozd SF; Gelperina SE; Pavlova GV; Khalansky AS Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(1):66-73. PubMed ID: 35170278 [TBL] [Abstract][Full Text] [Related]
98. Dose response and toxicity of doxorubicin microspheres in a rat tumor model. Napoli S; Burton MA; Martins IJ; Chen Y; Codde JP; Gray BN Anticancer Drugs; 1992 Feb; 3(1):47-53. PubMed ID: 1623216 [TBL] [Abstract][Full Text] [Related]